# US 2015/0104470 A1 · Immune modulation by peri-lymphatic or intra-lymphatic cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104470 A1
- Document ID: US20150104470A1
- Status: Published application
- Kind: A1
- Application number: 14/512,285
- Filed: 2014-10-10
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Inventors: Neil H. Riordan
- Web page: https://patentgrep.com/patent/US20150104470A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/48: Reproductive organs
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions of matter, methods of treatment, and protocols useful for therapeutic immune modulation using cell therapy administered perilymphatically or intralymphatically. In one particular embodiment, the invention provides means of treating an autoimmune condition by perilymphatic administration of a mesenchymal stem cell population. Said mesenchymal stem cell populations may be derived from umbilical cord tissues such as the Wharton's Jelly, amniotic membranes, or amniotic stem cells. In another particular embodiment Sertoli cells may be utilized as immune modulatory cells for the practice of the invention.

## Claims

### Claim 1

A method of immune modulating a mammal comprising identifying a mammal in need of immune modulation and administering an immune modulatory cell perilymphatically or intralymphatically into said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said immune modulatory cell is selected from a group of cells comprising of: a) mesenchymal stem cells; b) T regulatory cells; c) type 2 monocytes; d) CD5 positive B cells; e) type 2 NKT cells; f) tolerogenic dendritic cells; g) gamma delta T cells; h) T cells with immune regulatory properties; i) CD34 cells; j) very small embryonic like stem cells and k) Sertoli cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein said mesenchymal stem cell is derived from tissue comprising a group selected from: a) Wharton's Jelly; b) bone marrow; c) peripheral blood; d) mobilized peripheral blood; e) endometrium; f) hair follicle; g) deciduous tooth; h) testicle; i) adipose tissue; j) skin; k) amniotic fluid; l) cord blood; m) omentum; n) muscle; o) amniotic membrane; o) periventricular fluid; and p) placental tissue.

### Claim 4 (depends on 3)

The method of claim 3, wherein said mesenchymal stem cells express a marker or plurality of markers selected from a group comprising of: STRO-1, CD90, CD73, CD105, CD54, CD106, HLA-I markers, vimentin, ASMA, collagen-1, fibronectin, LFA-3, ICAM-1, PECAM-1, P-selectin, L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD61, CD18, CD29, thrombomodulin, telomerase, CD10, CD13, STRO-2, VCAM-1, CD146, and THY-1.

### Claim 5 (depends on 4)

The method of claim 4, wherein said mesenchymal stem cells do not express substantial levels of HLA-DR, CD117, and CD45.

### Claim 6 (depends on 3)

The method of claim 3, wherein said mesenchymal stem cells are generated from a pluripotent stem cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein said pluripotent stem cell is selected from a group comprising of: a) an embryonic stem cell; b) an inducible pluripotent stem cell; c) a parthenogenic stem cell; and d) a somatic cell nuclear transfer derived stem cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein said embryonic stem cell population expresses genes selected from a group comprising of: stage-specific embryonic antigens (SSEA) 3, SSEA 4, Tra-1-60 and Tra-1-81, Oct-3/4, Cripto, gastrin-releasing peptide (GRP) receptor, podocalyxin-like protein (PODXL), Rex-1, GCTM-2, Nanog, and human telomerase reverse transcriptase (hTERT).

### Claim 9 (depends on 7)

The method of claim 7, wherein said inducible pluripotent stem cell possesses markers selected from a group comprising of: CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, and HLA-A,B,C and possesses ability to undergo at least 40 doublings in culture, while maintaining a normal karyotype upon passaging.

### Claim 10 (depends on 7)

The method of claim 7, wherein said parthenogenic stem cells wherein said parthenogenically derived stem cells are generated by addition of a calcium flux inducing agent to activate an oocyte followed by enrichment of cells expressing markers selected from a group comprising of SSEA-4, TRA 1-60 and TRA 1-81.

### Claim 11 (depends on 7)

The method of claim 7, wherein said somatic cell nuclear transfer derived stem cells possess a phenotype negative for SSEA-1 and positive for SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase.

### Claim 12 (depends on 6)

The method of claim 6, wherein said mesenchymal stem cells are differentiated from a pluripotent stem cell source through culture in the presence of an inhibitor of the SMAD-2/3 pathway.

### Claim 13 (depends on 12)

The method of claim 12, wherein said mesenchymal stem cells are differentiated from a pluripotent stem cell source through culture in the presence of an inhibitor nucleic acid targeting the SMAD-2/3 pathway.

### Claim 14 (depends on 13)

The method of claim 13, wherein said nucleic acid inhibitor is selected from a group comprising of: a) an antisense oligonucleotide; b) a hairpin loop short interfering RNA; c) a chemically synthesized short interfering RNA molecule; and d) a hammerhead ribozyme.

### Claim 15 (depends on 13)

The method of claim 13, wherein said inhibitor of the SMAD-2/3 pathway is a small molecule inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein said small molecule inhibitor is SB-431542.

### Claim 17 (depends on 6)

The method of claim 6, wherein a selection process is used to enrich for mesenchymal stem cells differentiated from said pluripotent stem cell population.

### Claim 18 (depends on 17)

The method of claim 17, wherein said enrichment method comprises of positively selecting for cells expressing a marker associated with mesenchymal stem cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein said marker of mesenchymal stem cells is selected from a group comprising of: STRO-1, CD90, CD73, CD105, CD54, CD106, HLA-I markers, vimentin, ASMA, collagen-1, fibronectin, LFA-3, ICAM-1, PECAM-1, P-selectin, L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD61, CD18, CD29, thrombomodulin, telomerase, CD10, CD13, STRO-2, VCAM-1, CD146, and THY-1.

### Claim 20 (depends on 1)

The method of claim 1, wherein said immune modulatory cells are autologous, allogeneic or xenogeneic to the recipient.
